Regular short-acting β2-agonists administration in stable COPD

F. S. F. Ram, P. Sestini, P. W. Jones (London, United Kingdom; Siena, Italy)

Source: Annual Congress 2001 - COPD
Session: COPD
Session type: Poster Discussion
Number: 290
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. S. F. Ram, P. Sestini, P. W. Jones (London, United Kingdom; Siena, Italy). Regular short-acting β2-agonists administration in stable COPD. Eur Respir J 2001; 16: Suppl. 31, 290

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015


When to give corticosteroid inhalation therapy in stable COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

The use of intravenous aminophylline in treatment of exacerbations of COPD
Source: Annual Congress 2004 - Acute exacerbations and drug therapy in COPD
Year: 2004


Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015



Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013

Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 240s
Year: 2002

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Respiratory muscle strength after inhaled short acting beta-agonist administration in stable COPD patients
Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests
Year: 2012

Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Survey of dyspnoea in COPD patients on medication and preemptive use of a short-acting β-2 agonist
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009


Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids
Source: Eur Respir J 2016; 48: 558-560
Year: 2016


The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Nighttime short-acting beta-agonist (SABA) in asthma and COPD
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Year: 2019

Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016